Proteomics provides individualized options of precision medicine for patients with gastric cancer  

作　　者：Wenwen Huang Dongdong Zhan Yazhuo Li Nairen Zheng Xin Wei Bin Bai Kecheng Zhang Mingwei Liu Xuefei Zhao Xiaotian Ni Xia Xia Jinwen Shi Cheng Zhang Zhihao Lu Jiafu Ji Juan Wang Shiqi Wang Gang Ji Jipeng Li Yongzhan Nie Wenquan Liang Xiaosong Wu Jianxin Cui Yongsheng Meng Feilin Cao Tieliu Shi Weimin Zhu Yi Wang Lin Chen Qingchuan Zhao Hongwei Wang Lin Shen Jun Qin 

机构地区：[1]Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Peking University Cancer Hospital and Institute,Beijing 100142,China [2]State Key Laboratory of Proteomics,Beijing Proteome Research Center,National Center for Protein Sciences(Beijing),Beijing Institute of Lifeomics,Beijing 102206,China [3]Department of Pathology,The Fourth Medical Center of PLA General Hospital,Beijing 100048,China [4]State Key Laboratory of Cancer Biology,National Clinical Research Center for Digestive Diseases and Department of Digestive Surgery,Xijing Hospital of Digestive Diseases,Fourth Military Medical University,Xi’an 710032,China [5]Department of General Surgery&Institute of General Surgery,Chinese PLA General Hospital First Medical Center,Beijing 100853,China [6]Department of Gastrointestinal Surgery,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Peking University Cancer Hospital and Institute,Beijing 100142,China [7]Department of tumor biobank,Shanxi Cancer Hospital,Taiyuan 030013,China [8]Center for Bioinformatics and Computational Biology,Shanghai Key Laboratory of Regulatory Biology,Institute ofBiomedical Sciences and School of Life Sciences,East China Normal University,Shanghai 200241,China [9]State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development,School of Life Sciences,Institute of Biomedical Sciences,Fudan University,Shanghai 200433,China [10]Life Sciences Institute,Zhejiang University,Hangzhou 310058,China

出　　处：《Science China(Life Sciences)》2021年第8期1199-1211,共13页中国科学（生命科学英文版）

基　　金：supported by the National Key Research and Development Program of China(2017YFC1308900,2017YFC0908404,2018YFA0507503,2017YFA0505103);Beijing Municipal Government Key Research and Development Program(Z181100001918020,Z161100002616036);the National Natural Science Foundation of China(31870828,81972790,81672319);the Guangdong Provincial Key R&D Programmes(2019B020229002);the Science and Technology Program of Guangzhou(201902020009);the National Key Basic Research Program of China(2014CBA02002);the National Key Technology Support Program(2015BAI13B07).

摘　　要：While precision medicine driven by genome sequencing has revolutionized cancer care,such as lung cancer,its impact on gastric cancer(GC)has been minimal.GC patients are routinely treated with chemotherapy,but only a fraction of them receive the clinical benefit.There is an urgent need to develop biomarkers or algorithms to select chemo-sensitive patients or apply targeted therapy.Here,we carried out retrospective analyses of 1,020 formalin-fixed,paraffin-embedded GC surgical resection samples from 5 hospitals and developed a mass spectrometry-based workflow for proteomic subtyping of GC.We identified two proteomic subtypes:the chemo-sensitive group(CSG)and the chemo-insensitive group(CIG)in the discovery set.The 5-year overall survival of CSG was significantly improved in patients who had received adjuvant chemotherapy after surgery compared with those who received surgery only(64.2%vs.49.6%;Cox P-value=0.002),whereas no such improvement was observed in CIG(50.0%vs.58.6%;Cox P-value=0.495).We validated these results in an independent validation set.Further,differential proteome analysis uncovered 9 FDA-approved drugs that may be applicable for targeted therapy of GC.A prospective study is warranted to test these findings for future GC patient care.

关 键 词：PATIENTS CHEMOTHERAPY cancer 

分 类 号：R735.2[医药卫生—肿瘤]